Access to weight loss medication; Tirzepatide (also known as Mounjaro)

From 23 June 2025, people who meet the qualifying criteria (a BMI of at least 40 and four of the five stated weight related comorbidities), will be able to gain access to the drug via primary care, if both patient and clinician agree it is the most appropriate treatment option.

Full qualifying criteria is a BMI (Body Mass Index) of 40 plus and four or more of the following diagnosed health conditions:
– type 2 diabetes
– high blood pressure
– heart disease
– obstructive sleep apnoea
– abnormal blood fats (dyslipidaemia)

‘Access’ on 23 June does not mean people will be able to get a prescription for tirzepatide (Mounjaro) on that day. People living with obesity who meet the criteria will be able to explore with their healthcare professional whether this is the right treatment for them.

Access to tirzepatide (Mounjaro®) via the NHS is for those at greatest risk of ill health, or who are experiencing severe ill health due to living with obesity. Access to the drug must be accompanied by wraparound care which will include support for people to make dietary changes and to increase physical activity.

Early indications show that we have only a handful of patients eligible, who will be contacted once the ICB confirm a pathway for our area.